LUND, Sweden--()--Regulatory News:
“We are pleased to welcome Symrise as a new shareholder in Probi. Symrise has significant industrial expertise and a global network. There is currently no industrial collaboration between Probi and Symrise, but we intend to investigate the benefits of such a partnership”
The Probi (STO:PROB) probiotic company, which is listed on the Nasdaq OMX Nordic Exchange Stockholm, has gained a new industrial shareholder in the German company Symrise. Symrise has acquired a total of 1,102,301 shares, corresponding to 11.8 % of the capital and 12.1 % of the voting rights in the company, making it Probi’s largest shareholder. This information has been published in a notice disclosing a significant change in ownership.
Symrise is a leading global supplier of fragrances, flavourings, raw materials and functional ingredients. The company’s customers include leading manufacturers in the beauty, food and pharmaceutical industries and its products are used in a number of everyday items, including perfumes, bodycare products, textiles, healthcare products, consumer healthcare products, beverages, ready-made food, sweets and dairy products.
The company has two business areas: Flavor and Nutrition, which includes an extensive consumer healthcare division, and Scent and Care. The value chain of both business areas includes research, purchasing, product development, marketing, sales and customised solutions. The company’s focus is on developing innovative solutions and products for global customers in new markets. With a market share of approximately 10 %, Symrise is the world’s fourth largest supplier of fragrances and flavourings.
Symrise has nearly 5,500 employees and is active in 35 countries, with sales operations in 160 countries. The company’s sales in 2011 totalled approximately EUR 1.6 billion. Symrise has been listed on the Frankfurt Stock Exchange since 2006 under the ticker SY1.
“We are pleased to welcome Symrise as a new shareholder in Probi. Symrise has significant industrial expertise and a global network. There is currently no industrial collaboration between Probi and Symrise, but we intend to investigate the benefits of such a partnership,” says Michael Oredsson, CEO of Probi.
This information is such that Probi AB is required to disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.
Probi is a leading player in probiotic research and the development of efficient and well-documented probiotics. Its research areas include: gastrointestinal tracts, immune system, metabolic syndrome and stress and recovery. Probi’s customers are leading companies in the functional foods and consumer healthcare business areas. Income for 2011 totalled MSEK 95.0. Probi’s share is listed on the Nasdaq OMX Stockholm, Small Cap. Probi has approximately 5,000 shareholders. For more information, please visit www.probi.se.
For further information about Symrise, please visit www.symrise.com.
This information was brought to you by Cision http://www.cisionwire.com